Nicole DeFeudis
@nicoledefeudis.bsky.social
Biopharma reporter at Endpoints News | nicole@endpointsnews.com
The second round of Medicare price negotiations is now underway for all 15 selected drugs with signed agreements in place from the manufacturers of those drugs. endpts.com/all-selected...
All selected drugmakers agree to second round of price negotiations under the IRA
The second round of Medicare price negotiations is now underway for all 15 selected drugs with signed agreements in place from the manufacturers of those drugs.
endpts.com
March 17, 2025 at 8:16 PM
The second round of Medicare price negotiations is now underway for all 15 selected drugs with signed agreements in place from the manufacturers of those drugs. endpts.com/all-selected...
The Trump administration defended HHS’ rejection of drugmakers’ 340B rebate models “at this time." But when it comes to the companies’ proposed models, the agency specified that it “never said never.” endpts.com/trumps-hhs-d...
Trump’s HHS defends Biden-era stance on 340B rebate models
The Trump administration defended HHS’ rejection of drugmakers' 340B rebate models “at this time,” but suggested that the agency could be open to further consideration.
endpts.com
March 17, 2025 at 8:11 PM
The Trump administration defended HHS’ rejection of drugmakers’ 340B rebate models “at this time." But when it comes to the companies’ proposed models, the agency specified that it “never said never.” endpts.com/trumps-hhs-d...
“I do believe that any child who dies of a vaccine-preventable illness is a tragedy in the modern era,” FDA nominee Marty Makary said during a Senate hearing today. Read more here: endpts.com/makary-heari...
Live updates: Makary likely a lock for next FDA chief after breezy Senate hearing
Live updates from the Senate nomination hearing for Martin Makary, Trump's pick to lead the FDA.
endpts.com
March 6, 2025 at 7:44 PM
“I do believe that any child who dies of a vaccine-preventable illness is a tragedy in the modern era,” FDA nominee Marty Makary said during a Senate hearing today. Read more here: endpts.com/makary-heari...
A federal judge on Wednesday blocked the NIH from issuing a cap on indirect cost payments for grantees after finding that the challengers are likely to show the cuts conflict with the law. endpts.com/judge-grants...
Judge grants new nationwide block on NIH payment cuts
A federal judge on Wednesday blocked the NIH from issuing a cap on indirect cost payments for grantees after finding that the challengers are likely to show the cuts conflict with the law.
endpts.com
March 5, 2025 at 8:54 PM
A federal judge on Wednesday blocked the NIH from issuing a cap on indirect cost payments for grantees after finding that the challengers are likely to show the cuts conflict with the law. endpts.com/judge-grants...
Trump's NIH pick Jay Bhattacharya appears headed for a relatively easy Senate confirmation, following a two-hour hearing on Wednesday. The @endpts crew has minute-by-minute updates here: endpts.com/bhattacharya...
Live updates: Trump NIH pick Bhattacharya sails through Senate hearing, sidestepping controversy
Trump's NIH nominee Jayanta
endpts.com
March 5, 2025 at 5:59 PM
Trump's NIH pick Jay Bhattacharya appears headed for a relatively easy Senate confirmation, following a two-hour hearing on Wednesday. The @endpts crew has minute-by-minute updates here: endpts.com/bhattacharya...
Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain patients.
endpts.com/eli-lilly-ex...
endpts.com/eli-lilly-ex...
Eli Lilly expands Zepbound single-dose vial options at lower price
Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain patients.
endpts.com
February 25, 2025 at 1:26 PM
Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain patients.
endpts.com/eli-lilly-ex...
endpts.com/eli-lilly-ex...
An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block it.
endpts.com/nihs-funding...
endpts.com/nihs-funding...
NIH’s funding cut plan poses challenges for researchers despite court halt
An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block it.
endpts.com
February 12, 2025 at 9:27 PM
An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block it.
endpts.com/nihs-funding...
endpts.com/nihs-funding...
Reposted by Nicole DeFeudis
Our take: "A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far tougher day at a second Senate hearing on Thursday." Read our @endpts.com wrap, complete with comments throughout today's hearing. endpts.com/kennedy-hear...
Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers
A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far tougher day at a second Senate hearing on Thursday ...
endpts.com
January 30, 2025 at 7:04 PM
Our take: "A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far tougher day at a second Senate hearing on Thursday." Read our @endpts.com wrap, complete with comments throughout today's hearing. endpts.com/kennedy-hear...
Takeda CEO Christophe Weber will step down next June. Julie Kim, the current president of Takeda’s US business unit, will succeed Weber and will be the company’s first female CEO.
endpts.com/takeda-ceo-c...
endpts.com/takeda-ceo-c...
Takeda CEO Christophe Weber to retire in June 2026, Julie Kim to take over
Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker.
endpts.com
January 30, 2025 at 12:49 PM
Takeda CEO Christophe Weber will step down next June. Julie Kim, the current president of Takeda’s US business unit, will succeed Weber and will be the company’s first female CEO.
endpts.com/takeda-ceo-c...
endpts.com/takeda-ceo-c...
My Endpoints colleagues shared minute-by-minute updates on the Senate confirmation hearing for Robert F. Kennedy Jr. today. Check it out here:
endpts.com/kennedy-hear...
endpts.com/kennedy-hear...
RFK blog: Kennedy survives Senate grilling, with no bombshells to derail HHS confirmation
Through a contentious three-and-a-half-hour hearing, Robert F. Kennedy Jr. emerged relatively unscathed as the Senate considers his nomination for HHS secretary. Democratic senators grilled Kennedy ov...
endpts.com
January 29, 2025 at 9:24 PM
My Endpoints colleagues shared minute-by-minute updates on the Senate confirmation hearing for Robert F. Kennedy Jr. today. Check it out here:
endpts.com/kennedy-hear...
endpts.com/kennedy-hear...
The Trump administration said it will consider “opportunities to bring greater transparency” to the Medicare drug price negotiation process under the Inflation Reduction Act. CMS said it intends to get input from stakeholders.
endpts.com/trump-admini...
endpts.com/trump-admini...
Trump administration makes first comments on how it will run IRA drug negotiations
The Trump administration said on Wednesday it will consider
endpts.com
January 29, 2025 at 2:27 PM
The Trump administration said it will consider “opportunities to bring greater transparency” to the Medicare drug price negotiation process under the Inflation Reduction Act. CMS said it intends to get input from stakeholders.
endpts.com/trump-admini...
endpts.com/trump-admini...
AstraZeneca and Daiichi Sankyo redefined how breast cancer patients are classified when Enhertu was approved for HER2-low patients. Now they're expanding to "ultralow" patients.
endpts.com/astrazeneca-...
endpts.com/astrazeneca-...
AstraZeneca and Daiichi Sankyo's Enhertu approved in 'ultralow' HER2 patients
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer patients with very low levels of HER2 protein.
endpts.com
January 28, 2025 at 8:45 PM
AstraZeneca and Daiichi Sankyo redefined how breast cancer patients are classified when Enhertu was approved for HER2-low patients. Now they're expanding to "ultralow" patients.
endpts.com/astrazeneca-...
endpts.com/astrazeneca-...
Novo Nordisk is asking a federal appeals court to hurry up on its case challenging the Inflation Reduction Act’s drug pricing provisions.
endpts.com/novo-nordisk...
endpts.com/novo-nordisk...
Novo Nordisk asks Third Circuit to expedite IRA case as participation deadline looms
Novo Nordisk is asking a federal appeals court to make haste on its case challenging the Inflation Reduction Act's drug pricing provisions.
endpts.com
January 28, 2025 at 8:41 PM
Novo Nordisk is asking a federal appeals court to hurry up on its case challenging the Inflation Reduction Act’s drug pricing provisions.
endpts.com/novo-nordisk...
endpts.com/novo-nordisk...
Reposted by Nicole DeFeudis
NEW: I talked with George Yancopoulos on what he really makes of today's moment for AI
In his typical style, he has a few opinions on the topic:
endpts.com/regeneron-cs...
In his typical style, he has a few opinions on the topic:
endpts.com/regeneron-cs...
'No miracles': What Regeneron's George Yancopoulos really thinks of AI
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine. Agreeing to
endpts.com
January 22, 2025 at 1:04 PM
NEW: I talked with George Yancopoulos on what he really makes of today's moment for AI
In his typical style, he has a few opinions on the topic:
endpts.com/regeneron-cs...
In his typical style, he has a few opinions on the topic:
endpts.com/regeneron-cs...
AstraZeneca says it plans to participate in another round of Medicare negotiations under the IRA. But a company executive told me it's dealing with a whole new set of considerations this time around:
endpts.com/astrazeneca-...
endpts.com/astrazeneca-...
AstraZeneca exec stresses Calquence's patent life ahead of next Medicare negotiations
AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But this time around, the company says it’s dealing with a whole different set of...
endpts.com
January 22, 2025 at 11:32 PM
AstraZeneca says it plans to participate in another round of Medicare negotiations under the IRA. But a company executive told me it's dealing with a whole new set of considerations this time around:
endpts.com/astrazeneca-...
endpts.com/astrazeneca-...
Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare negotiation program under the Inflation Reduction Act. See the rest of the list here:
endpts.com/novo-nordisk...
endpts.com/novo-nordisk...
Ozempic makes list for next round of Medicare drug price negotiations
Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare negotiation program under the Inflation Reduction Act, following repeated ...
endpts.com
January 17, 2025 at 1:39 PM
Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare negotiation program under the Inflation Reduction Act. See the rest of the list here:
endpts.com/novo-nordisk...
endpts.com/novo-nordisk...
Reposted by Nicole DeFeudis
A pre-JPM Friday firehose of news:
Four biotechs emerge with $800M: endpts.com/four-biotech...
Former top Moderna scientist's new startup: endpts.com/modernas-for...
Obesity drug startup Metsera files IPO: endpts.com/obesity-drug...
Biogen offers to buy partner Sage: endpts.com/biogen-offer...
Four biotechs emerge with $800M: endpts.com/four-biotech...
Former top Moderna scientist's new startup: endpts.com/modernas-for...
Obesity drug startup Metsera files IPO: endpts.com/obesity-drug...
Biogen offers to buy partner Sage: endpts.com/biogen-offer...
Biogen offers to buy out struggling neuro partner Sage Therapeutics
Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long slid...
endpts.com
January 11, 2025 at 12:15 AM
A pre-JPM Friday firehose of news:
Four biotechs emerge with $800M: endpts.com/four-biotech...
Former top Moderna scientist's new startup: endpts.com/modernas-for...
Obesity drug startup Metsera files IPO: endpts.com/obesity-drug...
Biogen offers to buy partner Sage: endpts.com/biogen-offer...
Four biotechs emerge with $800M: endpts.com/four-biotech...
Former top Moderna scientist's new startup: endpts.com/modernas-for...
Obesity drug startup Metsera files IPO: endpts.com/obesity-drug...
Biogen offers to buy partner Sage: endpts.com/biogen-offer...
The @endpts.com Weekly has a new look! If you haven't already, sign up here to get our weekly recap of can't-miss biopharma news in your inbox on Saturday mornings: endpts.com/subscribe/
endpts.com/dna-edit-lea...
endpts.com/dna-edit-lea...
DNA edit leads to apparent cure in infant; CDER director to step down; More biotechs emerge with assets from China; and more
Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.
endpts.com
January 11, 2025 at 3:51 PM
The @endpts.com Weekly has a new look! If you haven't already, sign up here to get our weekly recap of can't-miss biopharma news in your inbox on Saturday mornings: endpts.com/subscribe/
endpts.com/dna-edit-lea...
endpts.com/dna-edit-lea...